Genelux (GNLX) Insider John Smither Buys 31,566 Shares
Insiders including John Smither picked up shares of Genelux Corporation on June 16, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
John Smither bought 31,566 shares of Genelux Corporation ($GNLX) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GNLX is down 3.6% after 1 week, down 6.9% after 1 month and down 20.1% to date (from the $3.03 close on Jun 16, 2026).
GNLX
Genelux Corporation
Key Points
- John Smither bought 31,566 shares of Genelux Corporation on June 16, 2026.
- The stock traded around $2.96 per share, sitting between its 52-week low of $2.29 and high of $8.54.
- Other insiders including Mary Mirabelli and James Tyree also acquired 31,566 shares each on the same date.
Get $GNLX trade alerts by text
We text you when insiders, Congress or big funds trade $GNLX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Genelux Corporation alert may contain errors. Disclosures
Genelux Corporation Insider Purchases Catch Attention
John Smither picked up 31,566 shares of Genelux Corporation on June 16, 2026. This purchase fits into a wider round of insider activity at the firm, coming alongside similar acquisitions by other key figures on the exact same day. The transaction adds fresh context to how leadership manages personal holdings in the business.
Recent Insider Activity at GNLX
The mid-June filing shows that John Smither wasn't the only one increasing exposure. Mary Mirabelli and James Tyree also acquired 31,566 shares each on June 16, 2026. These coordinated purchases form part of a broader round of insider transactions at the firm, following similar disclosures earlier in the month.
Stock Trades Near Moving Averages
Shares of Genelux Corporation changed hands around $2.96 recently, holding near its 200-day moving average of $2.93 and above its 50-day moving average of $2.72. The equity has moved between a 52-week low of $2.29 and a high of $8.54 over the past year. The firm carries a market capitalization of roughly $115.8 million.
Inside Genelux Corporation Operations
Genelux Corporation focuses on building viral immunotherapies aimed at fighting difficult-to-treat solid tumor types. Its lead candidate, Olvi-Vec, targets ovarian cancer through a modified strain of the vaccinia virus. The team operates out of Westlake Village, California, working to advance its platform and clinical pipeline.
What to Watch at GNLX
Observers will look toward upcoming SEC filings and corporate updates to track how these holdings evolve. Future reports from the company will provide further clarity on operational progress and pipeline milestones.
Related Filing Alerts
Source: John Smither's Form 4 filing on $GNLX (Jun 16, 2026). Find the original filing: GNLX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts